Cargando…
Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle
Traditionally, anti-platelet autoantibodies accelerating platelet clearance from the peripheral circulation have been recognized as the primary pathopysiological mechanism in chronic immune thrombocytopenia (ITP). Recently, increasing evidence supports the co-existence of insufficient megakaryopoies...
Autores principales: | Rank, Andreas, Weigert, Oliver, Ostermann, Helmut |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880346/ https://www.ncbi.nlm.nih.gov/pubmed/20531970 |
Ejemplares similares
-
Immune thrombocytopenic purpura
por: Zainal, Abir, et al.
Publicado: (2019) -
Update on chronic immune thrombocytopenic purpura (ITP)
por: McMillan, Robert
Publicado: (2009) -
Daratumumab for immune thrombotic thrombocytopenic purpura
por: van den Berg, Jana, et al.
Publicado: (2022) -
Long-term management of chronic immune thrombocytopenic purpura in adults
por: Palau, Javier, et al.
Publicado: (2010) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023)